For patients with symptomatic and severe tricuspid regurgitation (TR), tricuspid transcatheter edge-to-edge repair (T-TEER) ...

The Evoque transcatheter tricuspid valve replacement (TTVR) system continued to show significant benefits 1 year after ...

For patients with symptomatic and severe or greater tricuspid regurgitation (TR), transcatheter tricuspid valve replacement ...

Transcatheter tricuspid-valve replacement is superior to medical therapy alone for patients with severe tricuspid ...

The benefit was confined to symptoms, but in a very sick population with few options, that’s important, say researchers.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The Evoque transcatheter tricuspid valve replacement (TTVR) system continued to show significant benefits 1 year after ...

Edwards Lifesciences (NYSE:EW) today announced data highlighting the superiority of its Evoque system compared to medical ...

Israeli heart medical device company Innoventric today announced the completion of a $28.5 million Series B financing round.

The first year of data from the TRISCEND II study of the Evoque tricuspid valve by Edwards Lifesciences Corp. confirm the notion that reduced regurgitation has a big impact on patient well-being.

In this cohort study, the Kansas City Cardiomyopathy Questionnaire (KCCQ) had strong psychometric properties in patients with ...

Severe tricuspid regurgitation is associated with disabling symptoms and an increased risk of death. Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed.

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...